NewsBenzingaTakeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis Benzinga 2026.09.30 06:52 (GMT+0) Open on Benzinga Other news Petrovietnam Unit BSR Signs ExxonMobil Asia-Pacific Crude Supply Agreement Ensuring Minimum 2M Barrels Yearly For Dung Quat Refinery, Alongside Chevron Framework Pact DoorDash Expands India Footprint With Hyderabad Global Tech Hub, Adding To Pune Office, And Plans 3,000 Jobs Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review BA Stock Climbs After Boeing Secures $20 Billion Contract as Pentagon Pushes Next-Generation Carrier Fighter Program After Years of Delays Victory Capital Holdings: Multiple Pillars Of Growth (NASDAQ:VCTR) Telegram's built-in wallet "Wallet" renamed to Walt
Petrovietnam Unit BSR Signs ExxonMobil Asia-Pacific Crude Supply Agreement Ensuring Minimum 2M Barrels Yearly For Dung Quat Refinery, Alongside Chevron Framework Pact
DoorDash Expands India Footprint With Hyderabad Global Tech Hub, Adding To Pune Office, And Plans 3,000 Jobs
Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review
BA Stock Climbs After Boeing Secures $20 Billion Contract as Pentagon Pushes Next-Generation Carrier Fighter Program After Years of Delays
